• All
  • Financials
  • Insiders
Webull provides the latest Bellerophon (BLPH) stock and general news. This information may help you make smarter investment decisions.
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing the products that addresses unmet medical needs in the treatment of cardiopulmonary diseases. It is engaged in the development of nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using pulsatile nitric oxide delivery platform, INOpulse. INOpulse is a technology used in hospitals to deliver continuous flow of inhaled nitric oxide. Nitric oxide is naturally produced and released by the lining of the blood vessels and results in vascular smooth muscle relaxation, an important factor in regulating blood pressure. The Company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis as well as other pulmonary fibrosing diseases. The Company completed Phase II clinical trial.